1-4 of 4
Pablo Katz
Close
Sort by
Journal Articles

Clinical Profile and Long-Term Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab in a Real-World Setting: High Frequency of Anemia Despite Decreased Intravascular Hemolysis

Katharina Versmold, Ferras Alashkar, Carina Raiser, Richard Ofori-Asenso, Tao Xu, Yutong Liu, Pablo Katz, Aijing Shang, Alexander Roeth
Journal: Blood
Blood (2021) 138 (Supplement 1): 4314.
https://doi.org/10.1182/blood-2021-147162
Published: 2021
Journal Articles

Trial in Progress: A Real-World Cohort Study Reporting Patient Profiles, Clinical Outcomes, and Unmet Medical Need of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab in the Essen Center in Germany

Katharina Versmold, Carina Raiser, Imi Faghmous, BS, MSc, MA, MPH, PhD, Pablo Katz, MD, Aijing Shang, MD PhD, Tao Xu, Alexander Röth, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-140693
Published: 2020
Journal Articles

COMMODORE Cohort: A Novel, Real-World, Noninterventional Cohort Study Using a Patient-Centered Approach to Evaluate the Safety and Effectiveness of C5 Inhibitors in Patients with Paroxysmal Nocturnal Hemoglobinuria

Aijing Shang, MD PhD, Imi Faghmous, BS, MSc, MA, MPH, PhD, Dan Drozd, MD MSc, Pablo Katz, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–32.
https://doi.org/10.1182/blood-2020-137454
Published: 2020
Journal Articles

Trial in Progress: Quantifying the Humanistic and Socioeconomic Burden of Paroxysmal Nocturnal Hemoglobinuria in the COMMODORE Burden of Illness Study

Roger J Hampton, Pablo Katz, MD, Aijing Shang, MD PhD, Harpal Dhillon, Hayley Hubberstey, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-140679
Published: 2020